 |
|
Development of Generalized Disease at 2 Years in Patients With Ocular Myasthenia Gravis
Mark J. Kupersmith, MD;
Robert Latkany, MD;
Peter Homel, PhD
Arch Neurol. 2003;60:243-248.
Background Generalized myasthenia gravis will develop in more than 50% of patients who present with ocular myasthenia gravis, typically within 2 years. The optimal treatment of ocular myasthenia gravis, including the use of corticosteroids, remains controversial. In addition, the prevalence of thymoma and the optimal performance of the edrophonium chloride test for ocular myasthenia remain unknown.
Objective To assess the effect of oral corticosteroid therapy on the frequency of development of generalized myasthenia gravis within 2 years, the incidence of thymoma, and the amount of edrophonium needed for a positive test result in patients with ocular myasthenia gravis.
Methods We reviewed an ocular myasthenia gravis database of 147 patients. Patients underwent measurement of acetylcholine receptor (AChR) antibody levels and chest computed tomography. Unless contraindicated, patients with diplopia were recommended for therapy with prednisone, up to 40 to 60 mg/d, with the dosage tapered for 5 to 6 weeks. Most continued to receive daily or alternate-day doses of 2.5 to 10 mg to prevent diplopia. Patients not given prednisone (untreated group) received pyridostigmine bromide or no medication. After the diagnosis, we documented the signs and symptoms of ocular and generalized myasthenia gravis and performed 2-year follow-up in 94 patients.
Results The mean dose of edrophonium chloride to give a positive response was 3.3 mg (SD, 1.6 mg) for ptosis and 2.6 mg (SD, 1.1 mg) for ocular motor dysfunction. Thymoma occurred in 1 patient (0.7%). Generalized myasthenia gravis developed within 2 years in 4 of 58 treated and 13 of 36 untreated patients. The odds ratio (OR) for development of generalized disease in the treated group was 0.13 (95% confidence interval [CI], 0.04-0.45) compared with the untreated group. The AChR antibody level was not predictive of development of generalized myasthenia gravis at 2 years, but the risk was greater in patients with abnormal AChR antibody levels (OR, 6.33; 95% CI, 1.71-23.42). Logistic regression that included age, abnormal AChR antibody level, and prednisone therapy yielded significance only for abnormal AChR antibody level (OR, 7.03; 95% CI, 1.35-36.64) and treatment (OR, 0.06; 95% CI, 0.01-0.30).
Conclusions At 2 years, prednisone treatment appears to reduce the incidence of generalized myasthenia gravis to 7% in contrast to 36% of patients who did not receive prednisone. Thymoma, although uncommon, occurs in ocular myasthenia gravis. Only small amounts of edrophonium are needed to diagnose ocular myasthenia gravis.
From the Neuro-ophthalmology Service, Institute of Neurology and Neurosurgery, Beth Israel Medical Center (Drs Kupersmith and Homel), and the New York Eye and Ear Infirmary (Drs Kupersmith and Latkany), New York, NY.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Ocular Myasthenia Gravis Treatment: The Case Against Prednisone Therapy and Thymectomy
Gilbert et al.
Arch Neurol 2007;64:1790-1792.
FULL TEXT
Immunosuppressive or Surgical Treatment for Ocular Myasthenia Gravis
Chavis et al.
Arch Neurol 2007;64:1792-1794.
FULL TEXT
Evidence report: The medical treatment of ocular myasthenia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Benatar and Kaminski
Neurology 2007;68:2144-2149.
ABSTRACT
| FULL TEXT
Clinical and serological study of myasthenia gravis in HuBei Province, China
Zhang et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:386-390.
ABSTRACT
| FULL TEXT
Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment
Kupersmith and Ying
Br. J. Ophthalmol. 2005;89:1330-1334.
ABSTRACT
| FULL TEXT
Myasthenia Gravis: Generalized vs Ocular, and Children vs Adults
Wang
Arch Neurol 2003;60:1491-1491.
FULL TEXT
Development of Generalized Myasthenia Gravis in Patients With Ocular Myasthenia Gravis
Papapetropoulos et al.
Arch Neurol 2003;60:1491-1492.
FULL TEXT
|
